JP7190022B2 - 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法 - Google Patents

臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法 Download PDF

Info

Publication number
JP7190022B2
JP7190022B2 JP2021500737A JP2021500737A JP7190022B2 JP 7190022 B2 JP7190022 B2 JP 7190022B2 JP 2021500737 A JP2021500737 A JP 2021500737A JP 2021500737 A JP2021500737 A JP 2021500737A JP 7190022 B2 JP7190022 B2 JP 7190022B2
Authority
JP
Japan
Prior art keywords
cells
nkt cells
cik nkt
cik
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021500737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530224A (ja
Inventor
ロヒット ダッガール
ランジート シンハ
Original Assignee
イミュニティーバイオ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュニティーバイオ インコーポレイテッド filed Critical イミュニティーバイオ インコーポレイテッド
Publication of JP2021530224A publication Critical patent/JP2021530224A/ja
Priority to JP2022172004A priority Critical patent/JP7664207B2/ja
Application granted granted Critical
Publication of JP7190022B2 publication Critical patent/JP7190022B2/ja
Priority to JP2024202837A priority patent/JP2025015816A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021500737A 2018-07-10 2019-07-01 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法 Active JP7190022B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022172004A JP7664207B2 (ja) 2018-07-10 2022-10-27 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法
JP2024202837A JP2025015816A (ja) 2018-07-10 2024-11-21 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696131P 2018-07-10 2018-07-10
US62/696,131 2018-07-10
PCT/US2019/040145 WO2020014029A1 (en) 2018-07-10 2019-07-01 Generating cik nkt cells from cord blood

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022172004A Division JP7664207B2 (ja) 2018-07-10 2022-10-27 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法

Publications (2)

Publication Number Publication Date
JP2021530224A JP2021530224A (ja) 2021-11-11
JP7190022B2 true JP7190022B2 (ja) 2022-12-14

Family

ID=67551410

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021500737A Active JP7190022B2 (ja) 2018-07-10 2019-07-01 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法
JP2022172004A Active JP7664207B2 (ja) 2018-07-10 2022-10-27 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法
JP2024202837A Pending JP2025015816A (ja) 2018-07-10 2024-11-21 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022172004A Active JP7664207B2 (ja) 2018-07-10 2022-10-27 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法
JP2024202837A Pending JP2025015816A (ja) 2018-07-10 2024-11-21 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法

Country Status (9)

Country Link
US (2) US11931382B2 (enExample)
EP (1) EP3820994A1 (enExample)
JP (3) JP7190022B2 (enExample)
KR (3) KR102778139B1 (enExample)
CN (2) CN119372142A (enExample)
AU (2) AU2019300782B2 (enExample)
CA (1) CA3105601C (enExample)
IL (2) IL279924B2 (enExample)
WO (1) WO2020014029A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3174529A1 (en) * 2020-03-04 2021-09-10 Bioeclipse Therapeutics, Inc. Methods of manufacturing activated immune cells
US20230096410A1 (en) 2020-03-06 2023-03-30 Sorrento Therapeutics, Inc. Innate Immunity Killer Cells Targeting PSMA Positive Tumor Cells
CN111690607B (zh) * 2020-06-19 2022-02-18 珠海贝索细胞科学技术有限公司 一种高效杀伤细胞体外培养试剂盒及培养方法
CN112251407A (zh) * 2020-11-03 2021-01-22 广州康琪莱精准医疗科技有限公司 一种脐带血cik细胞的扩增培养方法
CN114807044B (zh) * 2021-04-30 2023-09-08 四川大学华西医院 一种具有高nkt细胞比例的car-cik细胞制备方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011052638A1 (ja) 2009-10-28 2011-05-05 タカラバイオ株式会社 サイトカイン誘導キラー細胞の製造方法
CN104017770A (zh) 2014-06-23 2014-09-03 山东赛乐中德生物科技有限公司 一种利用糖脂制备cik细胞的方法
US20170029777A1 (en) 2014-01-27 2017-02-02 St. Jude Children's Research Hospital, Inc. Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
BR9813981A (pt) 1997-11-06 2000-09-26 Roche Diagnostics Gmbh Antìgenos de tumor especìficos, métodos para a sua produção e seu uso imunização de diagnóstico
EP1117691A1 (en) 1998-10-05 2001-07-25 Ludwig Institute For Cancer Research Methods for producing human tumor antigen specific antibodies
US7098008B2 (en) 2000-04-25 2006-08-29 Ic&G Do. Ltd. Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use
KR20030032961A (ko) * 2000-06-06 2003-04-26 기린 비루 가부시키가이샤 내츄럴 킬러 ｔ 세포의 증폭 방법
WO2005014008A2 (en) * 2003-07-17 2005-02-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of disorders associated with natural killer t cells
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
US8012484B2 (en) * 2007-04-12 2011-09-06 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibiting NKT cell activity
AU2010347018A1 (en) * 2010-02-24 2012-09-20 Ingo Schmidt-Wolf Method for the generation of a CIK cell and NK cell population
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
ES2754394T3 (es) 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
JP6053688B2 (ja) 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
BR112014008849A2 (pt) 2011-10-20 2017-09-12 Us Health receptores quiméricos de antígeno anti-cd22
US20150225697A1 (en) 2012-08-13 2015-08-13 Anthrogenesis Corporation Natural killer cells and uses thereof
DK2893004T3 (en) 2012-09-04 2019-02-04 Cellectis MULTI-CHAIN CHEMICAL ANTIGEN RECEPTOR AND APPLICATIONS THEREOF
US20150329640A1 (en) 2012-12-20 2015-11-19 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
TWI702290B (zh) * 2015-04-07 2020-08-21 富禾生醫股份有限公司 經修飾之自然殺手ｔ細胞、醫藥組合物及其用途
CN106434552B (zh) * 2015-08-13 2022-04-29 清华大学 新型nkt样细胞亚群及其治疗肿瘤的用途
CN105176927B (zh) * 2015-10-15 2019-01-18 丛秀丽 一种细胞毒性增强的高效靶向杀伤nk/cik细胞的制备方法
CN106566807A (zh) * 2016-10-21 2017-04-19 闾军 一种浓度梯度rhIL‑2依赖的iNKT细胞扩增方法及其应用
CN106434556B (zh) * 2016-11-22 2019-10-11 上海新长安生物科技有限公司 一种体外诱导扩增i型nkt细胞的方法
EP3634437A4 (en) * 2017-05-19 2020-11-18 Case Western Reserve University COMPOSITIONS AND METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES
CN114258305A (zh) * 2019-08-21 2022-03-29 阿克索治疗公司 Iii型nkt细胞及相关组合物和方法
CN111172110B (zh) * 2019-12-20 2022-04-22 中科细胞科技(广州)有限公司 一种脐带血cik细胞的培养方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011052638A1 (ja) 2009-10-28 2011-05-05 タカラバイオ株式会社 サイトカイン誘導キラー細胞の製造方法
US20170029777A1 (en) 2014-01-27 2017-02-02 St. Jude Children's Research Hospital, Inc. Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof
CN104017770A (zh) 2014-06-23 2014-09-03 山东赛乐中德生物科技有限公司 一种利用糖脂制备cik细胞的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cytokine-induced killer cells are type II natural killer T cells，GMS German medical science，2007年，Vol.5，pp.1-4，https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2703238/参照
Pediatric Blood and Cancer，2010年09月15日，Vol. 55, No. 5，pp. 929, PN010

Also Published As

Publication number Publication date
US20220347218A1 (en) 2022-11-03
KR20210028675A (ko) 2021-03-12
CA3105601C (en) 2024-01-16
JP2023012503A (ja) 2023-01-25
IL279924B1 (en) 2025-04-01
JP7664207B2 (ja) 2025-04-17
CN112424343B (zh) 2024-10-22
IL279924A (en) 2021-03-01
AU2024200673A1 (en) 2024-03-07
KR20230133942A (ko) 2023-09-19
IL319500A (en) 2025-05-01
EP3820994A1 (en) 2021-05-19
CN119372142A (zh) 2025-01-28
US11931382B2 (en) 2024-03-19
KR102778139B1 (ko) 2025-03-10
KR102721222B1 (ko) 2024-10-24
IL279924B2 (en) 2025-08-01
AU2019300782A1 (en) 2021-01-14
AU2019300782B2 (en) 2023-12-21
KR102577954B1 (ko) 2023-09-14
JP2025015816A (ja) 2025-01-30
JP2021530224A (ja) 2021-11-11
CA3105601A1 (en) 2020-01-16
US20240180967A1 (en) 2024-06-06
KR20240154707A (ko) 2024-10-25
CN112424343A (zh) 2021-02-26
WO2020014029A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
JP7664207B2 (ja) 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法
Motohashi et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non–small cell lung cancer
JP6899333B2 (ja) 汎用キラーｔ細胞
KR102661091B1 (ko) Nk 세포의 골수 호밍을 개선시키는 pm21 입자
JP6096677B2 (ja) 同種造血幹細胞移植の増強
US9944898B2 (en) Method of generating tumor-specific T cells
KR101299299B1 (ko) 암면역 요법용 세포의 제조방법
US11351196B2 (en) Generating CIK NKT cells from cord blood
JP7546582B2 (ja) 治療に使用する細胞組成物を生成するためのガンマ・デルタｔ細胞のホーミング及び保持の方法
Asl et al. Intra-lesion injection of activated Natural Killer (NK) cells in recurrent Malignant brain tumors
Sánchez et al. Beyond CAR-T cells: Natural killer cells immunotherapy
JP2020502245A (ja) Ｃｃｒ２＋造血幹細胞は養子細胞療法におけるｔ細胞活性化を媒介する
US20200306302A1 (en) Treating and inhibiting leukemia with nk-92 cells
US12076344B2 (en) T-Rapa cells as novel effector cell type for chimeric antigen receptor therapy
HK40062462A (en) Method of homing and retention of gammadelta t cells, optionally using natural killer cells, for generating cell compositions for use in therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220613

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221027

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221027

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221104

TRDD Decision of grant or rejection written
C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221109

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221202

R150 Certificate of patent or registration of utility model

Ref document number: 7190022

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250